Join to view full profile
1470 Madison AveNew York, NY 10029
Phone+1 212-241-6756
Fax+1 214-645-2661
Dr. Kaur is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gurbakhash Kaur is a board-certified hematologist and oncologist practicing at Mount Sinai Hospital, part of the Icahn School of Medicine, in New York, NY. Her clinical focus lies in the treatment of multiple myeloma and other plasma cell disorders, including amyloidosis. Dr. Kaur is also highly experienced in advanced therapies, such as CAR-T cell therapy and stem cell transplantation. She received her medical degree from Drexel University College of Medicine and went on to complete an internal medicine residency at Tufts Medical Center. She then pursued specialized training in hematology and oncology through a fellowship at Montefiore Medical Center. Before joining Mount Sinai Hospital in October 2024, Dr. Kaur was affiliated with the University of Texas Southwestern from 2020 to 2024.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2016 - 2019
Tufts Medical CenterResidency, Internal Medicine, 2013 - 2016
Drexel University College of MedicineClass of 2013
Certifications & Licensure
NY State Medical License 2024 - 2028
NJ State Medical License 2019 - 2027
TX State Medical License 2020 - 2026
MA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.Rahul Banerjee, Hamza Hashmi, Preet M Chaudhary, Shebli Atrash, Kimberly Green
Advances in Therapy. 2026-08-19 - Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.Mahmoud R Gaballa, Kelley Julian, Aimaz Afrough, Doris K Hansen, Utkarsh Goel
Blood Advances. 2026-07-02 - Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid
Transplantation and Cellular Therapy. 2026-06-16
Lectures
- Body composition change, safety, and efficacy with everolimus use in ethnic minorities with breast cancer.2019 ASCO Annual Meeting - 6/1/2019
- Differentiating Lung Involvement in Adult T-Cell Leukemia Lymphoma (ATLL) Versus HTLV Infection: Results from a Large Single-Center Cohort with Implications for Stagin...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple MyelomaMay 14th, 2025- Exploring Educational Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield, DO, and Richa Thakur, MDOctober 25th, 2023
- Twice Weekly, Biweekly, or Somewhere in Between? Updates on Dosing Schedules in Multiple Myeloma With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MDOctober 25th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
